PMID- 19561292
OWN - NLM
STAT- MEDLINE
DCOM- 20091007
LR  - 20240319
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 14
IP  - 7
DP  - 2009 Jul
TI  - Role of hematopoietic stem cell transplant in the management of follicular 
      lymphoma.
PG  - 726-38
LID - 10.1634/theoncologist.2009-0045 [doi]
AB  - Despite decades of published data regarding the application of autologous and 
      allogeneic stem cell transplant in patients with follicular lymphoma, there 
      remain no uniform indications for its use in this disease. Autologous transplant 
      has been shown to lead to longer progression-free survival times in randomized 
      trials when compared with postremission interferon-based chemoimmunotherapy. 
      However, the development of rituximab and its use in frontline, salvage, and 
      maintenance therapy complicates the decision to pursue autologous transplant, a 
      modality developed prior to the advent of anti-CD20 monoclonal antibodies. 
      Allogeneic transplant offers the advantages of lymphoma-free grafts and the 
      immunologic graft-versus-lymphoma effect. These factors may confer the 
      possibility of long-term remission, though historically they have been 
      accompanied by high rates of upfront morbidity and mortality, especially in 
      heavily pretreated patients with a poor performance status or 
      chemotherapy-refractory disease. Advances in patient selection, human leukocyte 
      antigen (HLA) matching, conditioning regimens, and supportive care have reduced 
      transplant-related mortality and the incidence of graft-versus-host disease. 
      Recently published data focus on the incorporation of rituximab and 
      radioimmunoconjugates prior to, during, and following autologous transplant. 
      Furthermore, reduced-intensity allogeneic stem cell transplantation has 
      increasingly been used for relapsed follicular lymphoma patients with 
      comorbidities or advanced age. Several recent reports suggest that 
      reduced-intensity regimens may provide a high likelihood of long-term 
      disease-free survival for patients up to 70 years of age with a good performance 
      status, chemotherapy-sensitive disease, and HLA-matched sibling donors. Such 
      patients with relapsed disease should be referred to a transplant center that can 
      enroll them in one of the forthcoming clinical trials that aim to confirm these 
      outcomes.
FAU - Foster, Matthew
AU  - Foster M
AD  - Division of Hematology/Oncology, Department of Medicine, University of North 
      Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 
      27599-7305, USA. mcfoster@med.unc.edu
FAU - Gabriel, Don A
AU  - Gabriel DA
FAU - Shea, Thomas
AU  - Shea T
LA  - eng
GR  - T32 HL007149/HL/NHLBI NIH HHS/United States
GR  - T32 HL007149-31/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20090626
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antineoplastic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Antineoplastic Agents/therapeutic use
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Lymphoma, Follicular/*therapy
MH  - Rituximab
MH  - Transplantation Conditioning
PMC - PMC2948435
MID - NIHMS228956
EDAT- 2009/06/30 09:00
MHDA- 2009/10/08 06:00
PMCR- 2010/10/01
CRDT- 2009/06/30 09:00
PHST- 2009/06/30 09:00 [entrez]
PHST- 2009/06/30 09:00 [pubmed]
PHST- 2009/10/08 06:00 [medline]
PHST- 2010/10/01 00:00 [pmc-release]
AID - theoncologist.2009-0045 [pii]
AID - 10.1634/theoncologist.2009-0045 [doi]
PST - ppublish
SO  - Oncologist. 2009 Jul;14(7):726-38. doi: 10.1634/theoncologist.2009-0045. Epub 
      2009 Jun 26.